Obesity Treatment 'Wigobi' Starts Domestic Sales..."You should use it carefully for obese patients" [Anchor Report]

The obesity treatment "Wigobi," which is called the "dream diet medicine" and is very popular in the United States and Europe, has landed in Korea.

According to the pharmaceutical industry, the domestic distributor of WeGovi began taking orders for WeGovi today from local hospitals and pharmacies,
Developed by Novo Nordisk, a Danish pharmaceutical company called
Wigobi quickly went viral when foreign celebrities such as Elon Musk said it was effective.

As interest has increased in Korea, there have been a series of inquiries from obesity clinics and others since last year about "when Hugo Bee will be released."

It should be put on its own once a week on the arm, abdomen, and thighs, which are pen-like injections, and it is expected to be sold at a little more than 370,000 won for four times a month, and 700,000 won to consumers.

Clinical trials have shown that when administered for 68 weeks, the weight is reduced by an average of 15 percent, and it is also known to be effective in cardiovascular treatment.

However, as side effects such as headaches, vomiting, and diarrhea have been reported, doctors' prescriptions are essential when administering medications, and no one can get a prescription.

According to the Ministry of Food and Drug Safety, it can only be prescribed to obese patients with an initial BMI of 30 or higher and adult obese patients with a BMI of 27 to 30 and one or more comorbidities such as high blood pressure.

The company recorded more than 6 trillion won in global sales last year.

In Korea, attention is being paid to how much it will resonate.